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Research
Asbestos (CASRN 1332-21-4) is a known 
human carcinogen [International Agency for 
Research on Cancer (IARC) 1977]. Some 
types of asbestos fibers are still in use in many 
parts of the world today (Azari et al. 2010; 
Brims 2009; Burki 2010; Park et al. 2008). 
Exposure to various types of asbestos can lead 
to fibrotic lung disease (asbestosis); a range of 
non-neoplastic pleural pathologies including 
pleural plaques, diffuse pleural thickening, 
pleural effusions, and rounded atelectasis; and 
cancer. Several cancers are considered causally 
related to asbestos exposure, including lung 
cancer, pleural and peritoneal mesothelioma, 
laryngeal cancer, and ovarian cancer (Sanchez 
et al. 2009; Straif et al. 2009). Some indi-
vidual studies indicate possible associations 
between asbestos and other cancers, but the 
data are not sufficient to establish a causal 
link (e.g., pharyngeal, esophageal, stomach, 
and colorectal cancers). Numerous experi-
mental animal studies have demonstrated the 
carcinogenicity of fibers of the six commer-
cially used asbestos minerals [the serpentine 
chrysotile and the amphiboles cumming-
tonite-grunerite asbestos (amosite), tremolite 
asbestos, riebeckite asbestos (crocidolite), acti-
nolite asbestos, and anthophyllite asbestos] 
in multiple species (rats, hamsters, mice) by 
exposure via inhalation, intrapleural injection, 
implantation, and ingestion (reviewed by 
Kamp 2009; Lippmann 1990). Other adverse 
health outcomes of asbestos exposure, includ-
ing systemic effects such as autoimmune phe-
nomena, have also been investigated recently 
(Blake et al. 2007, 2008; Pfau et al. 2008).
Although commercial use of asbestos 
has decreased in the United States, some 
exposures to commercial asbestos continue 
as old asbestos-containing building stock is 
renovated or demolished and as the result 
of continuing importation of asbestos-
containing products such as brake pads and 
asbestos-containing cement products. In 
addition, as exposures to commercial asbestos 
have declined, exposures to non  commercial 
asbestos and other elongate mineral 
particles, often with different mineralogic 
characteristics and structures than fibers of 
the six commercially used asbestos minerals, 
have come into greater prominence. For 
example, exposures related to disturbance 
of contaminated soil by activities such as 
running, horseback riding, and use of all-
terrain vehicles have been a source of concern 
for a number of communities (Below et al. 
2011). Because there have been profound 
differences of opinion about whether these 
should be treated as asbestos exposures, they 
have often been highly controversial.
The general term “asbestos” was used for 
discussion purposes at this workshop, with 
clarification as to specific forms of asbestos 
included as needed. For ease of discussion, 
this general term will be used here as well to 
encompass asbestos and other elongate min-
eral fibers. Given the variability in the breadth 
of knowledge for specific mineral fibers, a full 
discussion of each type of asbestos fibers is 
beyond the scope of this summary report. 
The goal of the workshop was not to draw 
individual conclusions on adverse effects of 
specific mineral fibers, but to simply identify 
areas of agreement and uncertainty in the field 
of asbestos research in general. “Asbestos” 
refers to a family of elongate mineral particles 
with different physical and chemical charac-
teristics. The imprecise nature of this term 
contributes to miscommunication and uncer-
tainty in identifying toxicity associated with 
various forms of minerals, and is considered a 
key data gap in the field of asbestos research. 
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Ba c k g r o u n d: Although asbestos in general is well known to cause a range of neoplastic and 
  non-neoplastic human health effects, not all asbestos fiber types have the same disease-causing 
potential, and the mode of action (MOA) of specific types of asbestos and related fibers for various 
health outcomes are not well understood.
oBjectives: A workshop was held to discuss the state of the science of the MOA for asbestos-related 
disease. The objective was to review the range of asbestos-induced health effects (including those at 
sites remote to the respiratory tract). We sought to identify existing knowledge gaps and define 
what research is needed to address these gaps and advance asbestos research.
discussion: Discussions centered on areas of uncertainty in the field, including the ways asbestos 
is defined and characterized, the role of different fiber characteristics (e.g., length and mineralogy) 
in disease, and the impact of low-dose exposures on human health. Studying the dosimetry and 
mode of action of multiple fiber types would enhance our understanding of asbestos-related disease. 
To better elucidate the MOA of specific asbestos fibers, the risk assessor requires data as to specific 
characteristics of asbestos in determining fiber toxicity (e.g., surface area, mineral type), which may 
inform efforts to assess and control exposures and prevent adverse human health outcomes for the 
diverse range of fiber types. Specific research aims were defined for these topics and for overarch-
ing issues to be addressed, including the use of standardized terminology, test materials, and better 
experimental models to aid in data extrapolation to humans. 
co n c l u s i o n: To resolve these and other issues, participants agreed that diverse scientific disciplines 
must coordinate to better understand the MOA leading to the various asbestos-related disease 
end points. 
key w o r d s : asbestos, knowledge gaps, mineral fibers, mode of action, research needs. Environ Health 
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Although variability exists in the potency of 
various mineral fibers included in this general 
terminology, a full discussion of these differ-
ences was beyond the scope of the workshop.
Recently, the National Institute for 
Occupational Safety and Health (NIOSH) 
released a comprehensive report on the state 
of the science in asbestos and other mineral 
fibers, with a road map for future research 
in the field (NIOSH 2011). The document 
reflected review comments on an earlier draft 
report prepared by a multidisciplinary panel 
of experts [Institute of Medicine (IOM) and 
National Research Council 2009]. The pur-
pose of the document was to identify major 
knowledge gaps and uncertainties that needed 
to be resolved to allow NIOSH to update 
and develop evidence-based recommenda-
tions for asbestos fibers and other elongate 
mineral particles. This report recommends a 
broad research framework that can serve as 
a guide for development of specific research 
programs within and across disciplines. 
Recommendations included in this document 
also relate to the issues of terminology and 
definitions for asbestos and related mineral 
fibers (IOM and National Research Council 
2009). The reader is referred to both of these 
documents for a comprehensive review of the 
issues relative to asbestos terminology and the 
chemical and physical characteristics of fibers 
involved in disease induction.
Although the NIOSH Roadmap docu-
ment (NIOSH 2011) identifies toxicology 
research as a critical need for understanding 
the role of the various elongate mineral par-
ticles in disease, it does not address research 
elucidating the modes of action (MOAs) of 
asbestos and related mineral fibers in any 
detail. MOA encompasses a sequence of key 
events and processes starting with the inter-
action of a chemical with a cell and proceed-
ing through various steps to disease induction. 
Key questions still remain in understanding 
asbestos-induced health effects, particularly 
related to the MOAs of asbestos. The MOAs 
of asbestos for both carcinogenic and non-
carcinogenic health outcomes are not well 
understood. Identification of MOA for a 
toxic chemical or agent involves evaluation 
of physical, chemical, and biological informa-
tion to identify key events in how an agent 
results in carcinogenicity (U.S. Environmental 
Protection Agency 2005). An environmental 
agent like asbestos may work through more 
than one MOA, with multiple MOAs for 
various health outcomes (e.g., lung cancer vs. 
mesothelioma). MOA has been used predom-
inantly for understanding the assessment of 
cancer risk, but because dosimetry and other 
mechanisms of toxicity are shared across vari-
ous toxic effects, it is applied increasingly for 
noncancer risk assessment as well (Bogdanffy 
et al. 2001; Guyton et al. 2008).
Elucidating MOAs for the various health 
effects induced by asbestos is critical to fully 
understanding the impact of mineral fiber type, 
dimensions, and morphology on potential to 
induce toxicity. Not all asbestos fiber types 
have the same disease-causing potential, and 
studying the dosimetry and mode of action 
of multiple fiber types would enhance our 
understanding of these differences. The existing 
known mechanistic information on deposition, 
phagocytosis, reactive oxygen species (ROS) 
production, and gene expression alterations 
induced by asbestos exposure has been observed 
in both in vitro and in vivo research studies, 
but in many cases the role of these and other 
biological alterations as key events in human 
pathology and diseases are still being eluci-
dated. A particular knowledge gap for under-
standing modes of action for non  pulmonary 
health end points is clarification of the relative 
roles of direct effects of fiber translocation to 
extrapulmonary targets versus indirect systemic 
effects of fiber exposure mediated by agents 
such as cytokines or growth factors.
The NIEHS, along with other federal agen-
cies, held a workshop to address the current 
state of the science as it relates to the MOAs 
of asbestos and other related mineral fibers. Six 
main topic areas were defined before the work-
shop: health outcomes (pulmonary, pleural, 
and non  pulmonary), mutagenicity, susceptibil-
ity, and low-dose exposure response to fibers 
(Appendix 1). Based on their publication record 
and knowledge of the field, expert research-
ers were contacted by the workshop planning 
committee and asked to select and lead teams 
of experts to provide written reviews for each 
topic area for discussion at the workshop. 
Workshop discussants included these writing 
teams, invited reviewers recommended by these 
teams, and public observers. The complete 
reviews of each of these topics are published 
separately and include knowledge gaps and spe-
cific research needs (Aust et al. 2011; Below 
et al. 2011; Broaddus et al. 2011; Bunderson-
Schelvan et al. 2011; Case et al. 2011; Gwinn 
2011; Huang et al. 2011; Mossman et al. 
2011). Several cross-cutting issues were defined 
across the topic areas. Of particular interest 
were delineating areas of broad consensus versus 
areas of uncertainty. These issues and highlights 
of the workshop are summarized below.
Workshop Summary
Pulmonary disease after exposure to asbes-
tos is a well-studied area of asbestos-induced 
diseases. The MOAs of asbestos-induced pul-
monary effects appear to be different for the 
various adverse health outcomes (lung can-
cer, asbestosis, mesothelioma) and the various 
fiber types. An understanding of MOAs is 
hindered by potential confounding factors in 
human studies and limited characterization 
of fibers in most laboratory animal studies 
(Mossman et al. 2011). These limitations in 
fiber characterization contribute to some of 
the debate regarding the role of various fiber 
types and sizes in disease and make mechanis-
tic comparisons between fiber types difficult. 
One example is the continued controversy 
on the role of short fibers of various asbestos 
types in producing disease (Aust et al. 2011; 
Case et al. 2011; Mossman et al. 2011).
Along with mesothelioma, asbestos expo-
sure is associated with non-neoplastic inter-
stitial disease and pleural pathologies (e.g., 
plaques, diffuse pleural thickening, and effu-
sions). Despite the known association between 
asbestos exposure and pleural responses, ques-
tions still remain on the fundamental process 
of translocation of fibers to the pleural cavity. 
One experimental issue concerns the dissimi-
larities between the pleural cavities of differ-
ent species. Despite these differences, much 
has been learned about the mechanisms of 
pleural disease, particularly the interactions 
between fibers and target cells, both in the 
pleural cavities of laboratory animals and in 
in vitro studies using both animal and human 
cells (Broaddus et al. 2011).
Non  pulmonary effects after asbestos expo-
sure are not well understood. Strong support 
exists for an association between asbestos 
exposure and intra-abdominal processes such 
as peritoneal mesothelioma and ovarian carci-
noma (Straif et al. 2009). There is also some 
support, although data are limited, for auto-
immune effects associated with asbestos expo-
sure (Bunderson-Schelvan et al. 2011). The 
IARC concluded recently that the evidence 
linking asbestos exposure to stomach cancers is 
limited (Straif et al. 2009). Asbestos exposure 
may potentially lead to other non  pulmonary 
diseases; however, very few data exist to estab-
lish a causal relationship (Bunderson-Schelvan 
et al. 2011).
One of the more debated issues related to 
asbestos is whether specific asbestos fibers are 
mutagenic. Mutagenicity is a specific term 
that refers to a permanent, heritable change 
in the structure or amount of genetic material 
of an organism and includes gene mutations 
as well as structural and numerical alterations 
in chromosomes (Eastmond et al. 2009). 
Genotoxicity is a broader term, referring to 
the ability of a substance to damage DNA 
and/or cellular components that regulate the 
fidelity of the genome (e.g., spindle apparatus, 
DNA repair systems) (Eastmond et al. 2009). 
Although there is general agreement that some 
types of asbestos are genotoxic in vitro, either 
directly (i.e., fiber interactions with the spindle 
apparatus) or indirectly (i.e., ROS produc-
tion), there is less agreement on the muta-
genicity of asbestos fibers, particularly in vivo. 
Most genotoxicity studies of various types of 
asbestos have been performed in vitro, and 
therefore limited in vivo data are available to Gwinn et al.
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address this issue. An in-depth review of the 
existing literature (Huang et al. 2011) suggests 
a role for mutagenesis in asbestos-induced 
neoplastic diseases but not in non-neoplastic 
diseases. Thus, mutagenicity is one MOA for 
asbestos-induced neoplastic diseases, although 
this does not rule out a role for inflammation, 
cellular toxicity, and oxidative stress. These lat-
ter modes of action are believed to be involved 
in non-neoplastic disease as well.
Another area of increasing investigation 
is susceptibility to asbestos-induced diseases, 
particularly malignant mesothelioma (MM). 
There are limited studies examining the impact 
of age, sex, ethnicity or genetic makeup, dis-
ease status, and nutrition on asbestos-induced 
diseases. MM generally occurs late in life, and 
predominantly in men. However, because the 
majority of epidemiology studies are on male-
dominated occupational populations,   generally 
fewer females have been studied. The long 
latency period of MM is suggestive of multiple 
somatic genetic conversions after exposure to 
asbestos. Ionizing radiation (Goodman et al. 
2009) and some viral exposures (Yang et al. 
2008) have also been associated with suscep-
tibility to MM. Recent studies have also high-
lighted key biomarkers for MM, including 
soluble mesothelin-related peptide/megakaryo-
cyte potentiating factor (both encoded by the 
same gene) (Cristaudo et al. 2007; Pass et al. 
2008; Scherpereel and Lee 2007), osteopontin 
(Scherpereel and Lee 2007), and MN/CA9 (Li 
et al. 2007). Unfortunately, no one marker 
is specific to this tumor type. Ugolini et al. 
(2008) recently reviewed 20 reports of famil-
ial MM and determined that there is likely a 
polygenic component to this disease.
Discussion
The workshop participants highlighted some 
overarching issues that were considered obsta-
cles to progress in asbestos research. These 
include inconsistency in the use of the defi-
nition of asbestos fibers, a lack of standard 
size-selected reference materials, and an inad-
equate understanding of appropriate dose 
metric(s). Further, there is a need to better 
understand a) the potential for fiber-induced 
mutations that influence cancer, b) relevant 
mechanisms of translocation of different fiber 
types to extrapulmonary sites, c) health effects 
outside of the respiratory tract and pleural tis-
sue, and d) the role of population variability 
and sensitivity to asbestos-induced adverse 
health end points. The variability in approach 
to each of these areas impairs the ability to 
compare results across studies. Each overarch-
ing issue discussed is briefly described below 
and includes broad recommendations for 
future research in fiber toxicity.
Standardized terminology. The need for 
standardized terminology is paramount. There 
is no consensus on how to define terms as 
basic as “asbestos” and “fiber.” Agreement 
between the many disciplines and researchers 
interested in understanding the environmental 
(human and ecologic) effects of asbestos expo-
sure would greatly facilitate progress, because 
inconsistent use of terminology currently 
makes it difficult to compare results across 
the many existing studies. Recommendations 
from this workshop include that until stan-
dardized definitions are in place, research-
ers should at a minimum be encouraged to 
explicitly state their definitions and provide 
full fiber size distributions for the materi-
als used in experimental studies. The recent 
NIOSH Roadmap report (NIOSH 2011), in 
response to the NRC review (IOM/National 
Research Council 2009) of the draft docu-
ment, discusses issues related to appropriate 
terminology to be used in describing various 
types of asbestos fibers.
Sample characterization/measurement 
methods. Another overarching issue is the 
need for more explicit reporting of findings 
with respect to both definition of fiber and 
the type of sampling methods, including how 
fibers were quantified. Counting rules need 
to be well defined for results to be compared 
consistently and correctly between analytical 
laboratories. Counting rules include the fiber 
dimensions selected as the cutoff for inclusion 
in the fiber count, the total number of objects 
to be counted, and the methodology used. 
This is necessary to be able to rigorously com-
pare results across studies, and relates to limits 
of detection and how these limits may lead 
to truncation of fiber distributions that may 
be implicit in different experimental designs. 
There was a strong general agreement that it is 
necessary to perform a complete characteriza-
tion of all samples being compared and to fully 
describe this information, including counting 
rules, when publishing the results of a study. 
There are still some questions as to what consti-
tutes a full characterization and which methods 
are best suited to use for these purposes.
Standard size-selected reference   materials. 
It was recognized that the use of standard 
reference materials is also needed to assist in 
comparing research from multiple laboratories 
and test conditions. However, even if standard 
reference materials were made available for 
research, standard definitions for consistent 
characterization of materials used in research 
studies are still needed, as mentioned above. 
Size-selected test materials also are needed to 
disaggregate the influence of fiber dimension, 
morphology, and mineral form on specific 
toxic actions of fibers observed in both in vitro 
and in vivo experimental systems.
Defining the appropriate dose metric. 
Another key issue discussed by the workshop 
participants was related to identifying the 
appropriate dose metric to be used in asbes-
tos studies. As discussed above, there are key 
knowledge gaps regarding the role of physico-
chemical characteristics in asbestos-induced 
health effects. This makes the choice of a dose 
metric for any response analysis extremely 
important. Even though it is not clear which 
characteristics are important for understand-
ing relative differences between fiber types, 
it is clear that the standard use of mass alone 
is probably not sufficient. Comparisons 
between fiber types based solely on an equal 
mass basis do not take into account differences 
in fiber number, surface area, reactivity, or 
fiber dimensions in each sample. This can lead 
to erroneous conclusions about the relative 
potencies of fiber types, which can have serious 
ramifications. Rather than prescribe the defini-
tion of a dose metric a priori, studies should 
explore various dose metrics to ascertain which 
one best describes the exposure–response rela-
tionship for internal burdens at the organ or 
cellular levels as well as the exposure–response 
relationship for the given end point or out-
come measure under evaluation.
Development of novel experimental   systems. 
One of the primary reasons that uncertain-
ties exist in understanding the mechanistic 
response to asbestos is the lack of appropriate 
in vivo and in vitro test systems. There is a 
continued need for experimental systems that 
better reflect the MOAs for asbestos-induced 
disease in humans, specifically for pleural 
effects and translocation of fibers to the pleural 
space, as well as tissue-specific mutagenicity 
assays. More research is needed with appropri-
ate target cells (i.e., mesothelioma cells, Clara 
cells, alveolar epithelial cells) that is focused on 
the biological role those cells may have on the 
pathology of disease.
Genotoxicity of asbestos. The role of 
genotoxicity in asbestos-related diseases is 
unknown. Further, although existing data sug-
gest that alterations in gene expression and epi-
genetic effects may contribute to some types of 
asbestos fibers inducing disease, more research 
is needed to fully understand the complex 
and overlapping signaling pathways involved 
in these effects, including ROS production, 
DNA damage and repair and p53 activation, 
cell death (apoptosis or necrosis), and inflam-
mation. The interaction of these and other 
alterations leading to fiber-induced mutagenic-
ity is unclear. Another key issue related to can-
cer risk assessment of asbestos is whether there 
is a possible threshold exposure level (duration 
and magnitude) below which there is no geno-
toxic response after fiber exposure. Therefore, 
well-conducted in vitro and in vivo studies are 
needed to clarify this controversial issue.
Extrapolation to humans. It was recog-
nized that extrapolation of results from in vitro 
studies and in vivo laboratory animal studies to 
human populations is an important knowledge 
gap and research need. Although well-designed 
epidemiologic studies examining malignant Asbestos MOA workshop summary
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and non  malignant health effects of a range of 
fiber types after multiple routes of contempo-
rary exposure would be ideal for understand-
ing pathogenicity in humans, such populations 
are fortunately now rare. Furthermore, if iden-
tified, it would be unethical even to allow such 
exposure conditions to persist. In addition, 
human epidemiology studies are generally 
hindered by limited exposure information. 
Therefore, validated laboratory animal models 
(including primates) will be necessary to bet-
ter understand the dose response for various 
asbestos-related disease outcomes. These labo-
ratory animal models must be demonstrated to 
be relevant to human asbestos-induced adverse 
health effects to improve our understanding of 
pathogenesis and develop useful biomarkers.
Population variability and sensitivity. 
There is a major gap in understanding indi-
vidual susceptibility to the various types of 
asbestos-induced disease and variability in 
susceptibility across populations. Limited data 
are available regarding the impact of asbestos 
exposure in children, and the role of many 
preexisting health conditions on asbestos-
induced disease is unknown. Although the 
impact of certain coexposures such as smok-
ing has been known for decades (Selikoff et al. 
1968), limited information is available on the 
role of other coexposures. 
Conclusions
Even after decades of research, and numerous 
publications worldwide, the workshop par-
ticipants concluded that there are still major 
knowledge gaps hindering better understanding 
of the MOAs of various types of asbestos fibers.
Workshop participants agreed on a key 
overarching question: Is there sufficient under-
standing of the mechanisms of asbestos toxicity 
to determine the relevance of mineralogy and 
dimension in asbestos-induced disease? More 
specifically, do fibers < 5 µm in length have 
biological activity, and is there differential tox-
icity between serpentine and amphibole fibers? 
Although it is clear that fiber physicochemical 
characteristics play a role in asbestos-induced 
disease, it is less clear which characteristics are 
important to specific adverse health effects. In 
particular, discussion focused on the role of 
short fibers in disease. There are many research-
ers in the field who believe there is sufficient 
scientific evidence to show that short fibers 
(< 5 µm) do not play a role in inducing disease. 
However, others disagree with this conclusion. 
Similarly, consensus was not reached on the 
relative potency of different fiber types. Current 
knowledge regarding the characteristics that 
contribute to differences in relative potency 
between fiber types is incomplete, with a key 
research need being to systematically evaluate 
different fiber types. Participants agreed that 
although there is a wealth of information on 
mechanisms of asbestos-induced lung cancers, 
there is limited mechanistic understanding 
of how fiber mineralogy, dimensions, surface 
reactivity, and biopersistence contribute to all 
asbestos-induced diseases, particularly non-
pulmonary end points. Additional studies, both 
in vitro and in vivo, are needed to determine 
the role of specific physicochemical characteris-
tics from multiple fiber types in adverse health 
effects after exposure to asbestos and related 
mineral fibers.
One of the main objectives of this work-
shop was to bring together experts from 
diverse fields to encourage cross-fertilization of 
ideas to advance the field of asbestos research. 
Breakout group discussions from this work-
shop resulted in future multidisciplinary 
research ideas to address many of the existing 
knowledge gaps in the field. These included a 
follow-up workshop on standardized termi-
nology, increased inclusion of geologists in the 
planning and implementation of toxicology 
and epidemiology studies, and the need for 
increased research funding for large-scale inte-
grative multidisciplinary laboratory studies.
Appendix 1. Key topic areas for discussion at Asbestos MOA 
Workshop.
I.  Based on a mechanism/MOA, can we determine the range of fibers or specific compo-
nents that contribute to adverse health effects, keeping in mind the role of different fibers 
in various disease end points. A key consideration will be how to express the dose metric 
corresponding to different effect end points, e.g., fiber burden (milligrams or surface area) 
normalized to lung tissue volume.
A. Pulmonary end points (cancer and noncancer)
1. Deposition/translocation to the target organ.
2. Mechanisms required for fiber internalization by the cell (by fiber size).
3. Disease end points (mechanisms/MOA, fiber determinants of toxicity).
4. Any fibers considered inactive for a particular end point and why.
5. Dose metric options and issues of adjustment for sensitivity.
B. Pleural end points (cancer and noncancer)
1. Deposition/translocation to the target organ.
2. Mechanisms required for fiber internalization by the cell (by fiber size).
3. Disease end points (mechanisms/MOA, fiber determinants of toxicity).
4. Any fibers considered inactive for a particular end point and why.
5. Dose metric options and issues of adjustment for sensitivity.
C. Nonpulmonary end points (cancer and noncancer)
1. Deposition/translocation to the target organ.
2. Mechanisms required for fiber internalization by the cell (by fiber size).
3. Disease end points (mechanisms/MOA, fiber determinants of toxicity).
4. Any fibers considered inactive for a particular end point and why.
5. Dose metric options and issues of adjustment for sensitivity.
6. The role of fibrosis in carcinogenicity.
II.  Genetic toxicology
A. Role of mutagenicity in fiber-induced carcinogenicity
1. Is there a mutagenic MOA?
2. Mutagenicity/carcinogenicity at low doses.
3. Appropriate dosimetric for biological activity leading to mutagenicity and impact of 
target cell/tissue type.
4. Health end points with and without mutagenicity as a key event.
5. Influence of determinants of toxicity in mutagenicity.
III. Susceptibility






6. Lung architecture/ventilation patterns.
IV. Extrapolation of environmental exposure levels (low dose, sporadic, high dose) to health 
effects.
A. Role of lung exposure levels/regimen/determinants of toxicity
1. Lung architecture/ventilation patterns
2. Deposition, clearance, and overload
3. Inflammation
4. Mechanism of toxicity below inflammatory response.Gwinn et al.
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In conclusion, despite the breadth of the 
available literature on asbestos-induced health 
effects, unanswered questions still remain. 
The lack of clear answers may be attribut-
able partly to different interpretation of the 
existing data, which can be related to many 
of the over  arching research needs described 
above (rigorous attention to use of standard-
ized terminology, sampling characterization/
measurement methods, use of standard refer-
ence materials, and use of appropriate dose 
metrics). This workshop and the resulting 
state-of-the-science reviews seek to advance our 
understanding of the health hazards of differ-
ent types of asbestos fibers by identifying a) key 
knowledge gaps and b) the research needed to 
address these gaps to more fully understand 
determinants of toxic responses to asbestos and 
how asbestos exposures cause disease.
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